NCT07528911已完成不适用
Prognostic Significance of Adaptive Immunity Cell Infiltrates in the Microenvironment of High-grade Serous Ovarian Cancer
Hellenic Cooperative Oncology Group1 个研究点 分布在 1 个国家目标入组 687 人开始时间: 2023年4月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 687
- 试验地点
- 1
- 主要终点
- Assessment of: Tertiary Lymphoid Structures (presence, absence) in tumor biopsies
研究概览
简要总结
The study seeks to evaluate the presence and correlation with clinical outcome of several components of adaptive immunity (TILs, TLS, plasma cells and PD-L1 expression) in tumor specimens of patients with EOC treated with carboplatin/paclitaxel chemotherapy.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patients with advanced high grade serous ovarian cancer treated with carboplatin/paclitaxel chemotherapy
排除标准
- •Any other histology than high grade ovarian cancer
- •Patients with stages I-II (based on FIGO staging)
研究组 & 干预措施
Patients with high grade serous ovarian cancer treated with chemotherapy
干预措施: Assessment of elements of adaptive immunity in tumor biopsies (Other)
结局指标
主要结局
Assessment of: Tertiary Lymphoid Structures (presence, absence) in tumor biopsies
时间窗: through study completion, an average of 3 years
次要结局
- CD8 cells (low : <5 cells/HPF vs high (> 5 cells/HPF) expression) in tumor biopsies(upron study completion (3 years))
- Plasma cells (4-tiered score)(3- years time frame (upon study completion))
- PD-L1 score (TPS score) in tumor biopsies(upon study completion (3 years))
- p53 (presence, absence) in tumor biopsies (immunohistochemistry)(upon study compeltion (3 years))
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
不适用
Mechanisms of Precise Immune Cell Phenotyping and Prognostic Prediction in Severe InfectionSepsisNCT07332793Second Affiliated Hospital of Wenzhou Medical University200
招募中
不适用
Prognostic Value of SII and SIRI in Obesity-Related Metabolic ComplicationsNCT07431593University of Rijeka200
Unknown
不适用
免疫功能与新冠病毒感染患者预后的关系及其对临床结局的预测价值ChiCTR2300069371自筹
Unknown
不适用
对接受特异性免疫治疗患者疾病进展、表型、内型及相关生物学因素的前瞻性、队列研究ChiCTR2200065686研究申办医院100
招募中
不适用
Monitoring of Immunological Mechanisms and Biomarkers Underlying Efficacy of Immunotherapy in Patients With Early Stage CancerNCT07427186Institut Claudius Regaud600